Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
GeneFrontier Japan
Sakai, Japan
A
- Employees
2010
Key takeaway
The company specializes in protein engineering and biologics, focusing on innovative therapeutic antibody candidates. Their expertise includes phage display technology and the development of high-functionality antibodies.
Reference
Product
Drug Discovery | 日本語版
mAbProtein
Izumo, Japan
A
1-10 Employees
2018
Key takeaway
mAbProtein is focused on driving innovation in antibody development, which may include advancements related to bispecific antibodies.
Reference
Core business
マブプロテイン｜抗体製造 mAbProtein | 島根大学発のバイオベンチャー
Molcure
Tokyo, Japan
A
11-50 Employees
2013
Key takeaway
The company utilizes proprietary methods and AI technology to identify valuable antibodies and peptides, focusing on predicting key properties of biopharmaceuticals. Their innovative approach includes directed evolution experiments and advanced machine learning models, which could be relevant for the development of bispecific antibodies.
Reference
Core business
Molcure Inc. | Accelerating drug discovery
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
T Cell Nouveau
Tokyo, Japan
A
1-10 Employees
2021
Key takeaway
The company, T Cell Nouveau Inc., is advancing cancer treatment through its innovative TCR-like CAR T-cell therapy, which targets solid tumors that are resistant to conventional therapies. Their patented TCR-like CAR antibodies demonstrate high specificity for target antigens, highlighting their commitment to cutting-edge immunotherapeutics.
Reference
Core business
Car-t細胞療法 | T Cell Nouveau、ティーセルヌーヴォー株式会社 | 東京都
ティーセルヌーヴォー株式会社は臨床段階のバイオメディカル企業であり、三重大学 珠玖研究室が開発した最先端のTCR like CAR-T細胞療法を用いて、免疫系を賦活化することにより固形がんを治療することを目指しています。私たちのユニークなTCR like CAR T細胞療法は、近年のCAR-T細胞療法あるいはTCR-T細胞療法が奏功しない固形がんの治療を目指す飛躍的な革新技術であると強く信じています。私たちの特許技術であるTCR like CAR抗体は、ペプチド-HMC複合体における標的抗原（MAGE4またはPRAME）に対して高い特異性を有しています。さらに、私たちの特許技術であるシグナルドメイン構造は、免疫抑制性のがん微小環境において、T cell機能の活性化、維持及び持続を助けます。
AceRNA
Kyoto, Japan
A
1-10 Employees
2018
Key takeaway
The company is focused on developing novel genetic therapies that specifically target disease-causing cells, which aligns with the innovative approaches often associated with bispecific antibodies. Their commitment to creating targeted treatments using advanced technologies like RNA Switches highlights their potential in the field of precision medicine.
Reference
Core business
News - aceRNA
aceRNA
ReproCELL
Yokohama, Japan
A
51-100 Employees
2003
Key takeaway
REPROCELL offers a diverse range of antibodies and staining kits, which could be valuable for research involving bispecific antibodies. Additionally, the company has expertise in developing novel regenerative medicine therapies and conducting clinical trials, highlighting its commitment to advancing translational research.
Reference
Product
Products: Antibodies and Staining Kits
Browse a range of antibodies and staining kits on the REPROCELL website. Request a quote for delivery to the USA or Europe today.
Libero Thera
Osaka, Japan
A
1-10 Employees
2018
Key takeaway
LiberoThera Co., Ltd. is focused on innovative drug development, particularly in antibody therapeutics targeting GPCRs, utilizing their unique cell-free membrane protein preparation and non-natural amino acid incorporation technologies.
Reference
Core business
リベロセラ株式会社 - 無細胞膜タンパク質調製技術 および 非天然型アミノ酸導入技術 を用いた革新的な創薬を通じ医療に貢献します。
無細胞膜タンパク質調製技術 および 非天然型アミノ酸導入技術 を用いた革新的な創薬を通じ医療に貢献します。 - GPCRを標的とした抗体医薬を中心に創薬を行っています。
Beyond Next Ventures
Tokyo, Japan
A
1-10 Employees
2014
Key takeaway
The company, Beyond Next Ventures, is dedicated to supporting researchers and entrepreneurs in the deep tech sector, including drug discovery and biotech. They provide essential resources such as financial assistance, incubation facilities, and business development support, which could be valuable for those working on bispecific antibodies and other innovative therapies.
Reference
Product
Drug discovery / Biotech | Beyond Next Ventures
001
AccuRna
Tokyo, Japan
A
1-10 Employees
2015
Key takeaway
AccuRna is focused on advancing drug delivery systems for nucleic acid therapeutics, which may encompass innovations relevant to bispecific antibodies in their pursuit of effective treatments for refractory diseases. Their commitment to developing robust delivery mechanisms highlights their role in the evolving landscape of targeted therapies.
Reference
Product
Therapeutic Vaccine – AccuRna, Inc.
Arigen Pharmaceuticals
Tokyo, Japan
A
11-50 Employees
2001
Key takeaway
The company is focused on innovative trifunctional CIRs that selectively mark serum antibodies and direct immune responses towards specific target proteins, which is relevant to the development of bispecific antibodies. Additionally, they emphasize process improvements in drug development to enhance the success rates of preclinical candidates.
Reference
Product
Products for the Life Science Industry ⇒ bionity.com
Technologies which have been searched by others and may be interesting for you:
The Bispecific Antibody industry in Japan presents unique opportunities and challenges for those interested in this field. A critical consideration is the stringent regulatory environment, governed by the Pharmaceuticals and Medical Devices Agency (PMDA), which oversees the approval process for biopharmaceuticals. Companies must navigate complex clinical trial requirements and ensure compliance with local regulations to successfully bring products to market. Another factor is the competitive landscape, which includes both established pharmaceutical giants and emerging biotech firms. Collaboration and partnerships are common, as they allow companies to enhance their research capabilities and expedite development timelines. Additionally, Japan's aging population drives demand for innovative therapies, creating a favorable market environment for bispecific antibodies. However, companies must also be aware of environmental concerns, particularly regarding the sustainability of production processes and waste management. As global market relevance grows, Japan's firms are increasingly looking to expand their reach internationally, necessitating an understanding of global trends and market dynamics. Overall, thorough research into regulatory requirements, competitive strategies, and market demands is essential for anyone exploring the Bispecific Antibody industry in Japan.
Some interesting numbers and facts about your company results for Bispecific Antibody
| Country with most fitting companies | Japan |
| Amount of fitting manufacturers | 20 |
| Amount of suitable service providers | 7 |
| Average amount of employees | 1-10 |
| Oldest suiting company | 2001 |
| Youngest suiting company | 2021 |
Some interesting questions that has been asked about the results you have just received for Bispecific Antibody
What are related technologies to Bispecific Antibody?
Based on our calculations related technologies to Bispecific Antibody are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of Bispecific Antibody?
Start-Ups who are working in Bispecific Antibody are T Cell Nouveau
Which industries are mostly working on Bispecific Antibody?
The most represented industries which are working in Bispecific Antibody are Other, Biotechnology, IT, Software and Services, Chemicals, Electronics and Electrical engineering
How does ensun find these Bispecific Antibody Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.